UCB - Public Comps and Valuation Multiples

UCB Overview

About UCB

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Founded

1928

HQ

Employees

9.4K+

Website

ucb.com

Sectors

Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue $8.1B

LTM EBITDA $2.4B

EV

$55.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

UCB Financials

As of September 2025, UCB reported last 12-month revenue of $8.1B and EBITDA of $2.4B.

In the same period, UCB generated $6.0B in LTM gross profit and $1.3B in net income.

See UCB valuation multiples based on analyst estimates

UCB P&L

In the most recent fiscal year, UCB reported revenue of $7.1B and EBITDA of $2.3B.

UCB expects next 12-month revenue of XXX and NTM EBITDA of XXX

See UCB valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$8.1B	XXX	$7.1B	XXX	XXX	XXX
Gross Profit	$6.0B	XXX	$5.1B	XXX	XXX	XXX
Gross Margin	74%	XXX	72%	XXX	XXX	XXX
EBITDA	$2.4B	XXX	$2.3B	XXX	XXX	XXX
EBITDA Margin	29%	XXX	32%	XXX	XXX	XXX
EBIT	$1.7B	XXX	$999M	XXX	XXX	XXX
EBIT Margin	21%	XXX	14%	XXX	XXX	XXX
Net Profit	$1.3B	XXX	$1.2B	XXX	XXX	XXX
Net Margin	17%	XXX	17%	XXX	XXX	XXX
Net Debt	XXX	XXX	$1.4B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for UCB including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $8.1B. EBITDA for the last twelve months was $2.4B. In the most recent fiscal year, UCB achieved $7.1B in revenue and $2.3B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$8.1B	Analyst estimates available to subscribers	$7.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$6.0B	Analyst estimates available to subscribers	$5.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	73.9% gross margin	Analyst estimates available to subscribers	71.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$2.4B	Analyst estimates available to subscribers	$2.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	29.4% EBITDA margin	Analyst estimates available to subscribers	31.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$1.7B	Analyst estimates available to subscribers	$999M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	21.3% EBIT margin	Analyst estimates available to subscribers	14.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$1.3B	Analyst estimates available to subscribers	$1.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	16.5% net profit margin	Analyst estimates available to subscribers	17.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$1.4B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for UCB

This financial data table provides comprehensive performance metrics for UCB, a company based in Belgium. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

UCB generated $8.1B in revenue over the last twelve months.
The company achieved $2.4B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $6.0B.
Net income over the last twelve months reached $1.3B.

Fiscal Year Performance

In the most recent fiscal year, UCB reported $7.1B in total revenue.
Fiscal year EBITDA was $2.3B.
The company maintained a gross profit margin of 71.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 31.9%.
Net profit margin reached 17.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for UCB. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

UCB Stock Performance

UCB has current market cap of EUR 47.2B (or $54.6B), and EV of EUR 48.1B (or $55.6B).

Market Cap Evolution

UCB Stock Data

As of October 17, 2025, UCB's stock price is EUR 249 (or $288).

See UCB trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$55.6B	$54.6B	XXX	XXX	XXX	XXX	$8.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

UCB Valuation Multiples

UCB's trades at 7.8x EV/Revenue multiple, and 24.5x EV/EBITDA.

See valuation multiples for UCB and 15K+ public comps

UCB Financial Valuation Multiples

As of October 17, 2025, UCB has market cap of $54.6B and EV of $55.6B.

Equity research analysts estimate UCB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

UCB has a P/E ratio of 40.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$54.6B	XXX	$54.6B	XXX	XXX	XXX
EV (current)	$55.6B	XXX	$55.6B	XXX	XXX	XXX
EV/Revenue	6.9x	XXX	7.8x	XXX	XXX	XXX
EV/EBITDA	23.3x	XXX	24.5x	XXX	XXX	XXX
EV/EBIT	32.1x	XXX	55.7x	XXX	XXX	XXX
EV/Gross Profit	9.3x	XXX	n/a	XXX	XXX	XXX
P/E	40.8x	XXX	44.4x	XXX	XXX	XXX
EV/FCF	34.6x	XXX	52.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get UCB Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

UCB Margins & Growth Rates

UCB's last 12 month revenue growth is 15%

UCB's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.4M for the same period.

UCB's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

UCB's rule of X is 68% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for UCB and other 15K+ public comps

UCB Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	15%	XXX	16%	XXX	XXX	XXX
EBITDA Margin	29%	XXX	32%	XXX	XXX	XXX
EBITDA Growth	33%	XXX	32%	XXX	XXX	XXX
Rule of 40	40%	XXX	47%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	68%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	34%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	29%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	57%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial

UCB Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps

	EV/Revenue			EV/EBITDA
	2025E	2026E	2027E	2025E	2026E	2027E
CSL	XXX	XXX	XXX	XXX	XXX	XXX
Imugene	XXX	XXX	XXX	XXX	XXX	XXX
Prescient Therapeutics	XXX	XXX	XXX	XXX	XXX	XXX
GSK India	XXX	XXX	XXX	XXX	XXX	XXX
AstraZeneca India	XXX	XXX	XXX	XXX	XXX	XXX
XXXXXXXX	XXX	XXX	XXX	XXX	XXX	XXX
XXXXXXXX	XXX	XXX	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc.

UCB M&A and Investment Activity

UCB acquired XXX companies to date.

Last acquisition by UCB was XXXXXXXX, XXXXX XXXXX XXXXXX . UCB acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).

See M&A valuation multiples

Latest Acquisitions by UCB

Acquired Company	EV	EV/Revenue	EV/EBITDA
XXXXXXXXX	XXX	XXX	XXX
XXXXXXXXX	XXX	XXX	XXX
XXXXXXXXX	XXX	XXX	XXX
XXXXXXXXX	XXX	XXX	XXX
XXXXXXXXX	XXX	XXX	XXX

Get Verified M&A Valuation Multiples

Start Free Trial

About UCB

When was UCB founded?	UCB was founded in 1928.
Where is UCB headquartered?	UCB is headquartered in Belgium.
How many employees does UCB have?	As of today, UCB has 9.4K+ employees.
Who is the CEO of UCB?	UCB's CEO is Mr. Jean-Christophe Tellier.
Is UCB publicy listed?	Yes, UCB is a public company listed on BRU.
What is the stock symbol of UCB?	UCB trades under UCB ticker.
When did UCB go public?	UCB went public in 1988.
Who are competitors of UCB?	Similar companies to UCB include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of UCB?	UCB's current market cap is $54.6B
What is the current revenue of UCB?	UCB's last 12 months revenue is $8.1B.
What is the current revenue growth of UCB?	UCB revenue growth (NTM/LTM) is 15%.
What is the current EV/Revenue multiple of UCB?	Current revenue multiple of UCB is 6.9x.
Is UCB profitable?	Yes, UCB is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of UCB?	UCB's last 12 months EBITDA is $2.4B.
What is UCB's EBITDA margin?	UCB's last 12 months EBITDA margin is 29%.
What is the current EV/EBITDA multiple of UCB?	Current EBITDA multiple of UCB is 23.3x.
What is the current FCF of UCB?	UCB's last 12 months FCF is $1.6B.
What is UCB's FCF margin?	UCB's last 12 months FCF margin is 20%.
What is the current EV/FCF multiple of UCB?	Current FCF multiple of UCB is 34.6x.

UCB Valuation Multiples

Discover revenue and EBITDA valuation multiples for UCB and similar public comparables like GSK India, Imugene, and AstraZeneca India.

UCB Overview

About UCB

Founded

HQ

Employees

Website

Sectors

Financials

EV

Valuation Multiples

Valuation Multiples for 15K+ Public Comps

UCB Financials

UCB P&L

Financial Performance Summary for UCB

Recent Performance Highlights

Fiscal Year Performance

UCB Stock Performance

Market Cap Evolution

UCB Stock Data

Benchmark Trading Valuation Multiples by Industry

UCB Valuation Multiples

EV/Revenue (LTM) Evolution

UCB Financial Valuation Multiples

Get UCB Valuation Multiples

UCB Margins & Growth Rates

UCB Operational Valuation Multiples

Valuation Multiples Across 220+ Verticals

UCB Public Comps

UCB M&A and Investment Activity

Latest Acquisitions by UCB

Get Verified M&A Valuation Multiples

About UCB

Join Now Or Talk To Us

Join Our Newsletter